Endothelial cell-activating antibodies in COVID-19
ABSTRACT Objective While endothelial dysfunction has been implicated in the widespread thrombo-inflammatory complications of coronavirus disease-19 (COVID-19), the upstream mediators of endotheliopathy remain for the most part cryptic. Our aim was to identify circulating factors contributing to endothelial cell activation and dysfunction in COVID-19.Methods Human endothelial cells were cultured in the presence of serum or plasma from 244 patients hospitalized with COVID-19 and plasma from 100 patients with non-COVID sepsis. Cell adhesion molecules (E-selectin, VCAM-1, and ICAM-1) were quantified by in-cell ELISA.Results Serum and plasma from patients with COVID-19 increased surface expression of cell adhesion molecules. Furthermore, levels of soluble ICAM-1 and E-selectin were elevated in patient serum and tracked with disease severity. The presence of circulating antiphospholipid antibodies was a strong marker of the ability of COVID-19 serum to activate endothelium. Depletion of total IgG from antiphospholipid antibody-positive serum markedly restrained upregulation of cell adhesion molecules. Conversely, supplementation of control serum with patient IgG was sufficient to trigger endothelial activation.Conclusion These data are the first to suggest that some patients with COVID-19 have potentially diverse antibodies that drive endotheliopathy, adding important context regarding thrombo-inflammatory effects of autoantibodies in severe COVID-19..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 25. Mai Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shi, Hui [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2021.01.18.21250041 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019784074 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019784074 | ||
| 003 | DE-627 | ||
| 005 | 20230429095247.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210122s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.01.18.21250041 |2 doi | |
| 035 | |a (DE-627)XBI019784074 | ||
| 035 | |a (biorXiv)10.1101/2021.01.18.21250041 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Shi, Hui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endothelial cell-activating antibodies in COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Objective While endothelial dysfunction has been implicated in the widespread thrombo-inflammatory complications of coronavirus disease-19 (COVID-19), the upstream mediators of endotheliopathy remain for the most part cryptic. Our aim was to identify circulating factors contributing to endothelial cell activation and dysfunction in COVID-19.Methods Human endothelial cells were cultured in the presence of serum or plasma from 244 patients hospitalized with COVID-19 and plasma from 100 patients with non-COVID sepsis. Cell adhesion molecules (E-selectin, VCAM-1, and ICAM-1) were quantified by in-cell ELISA.Results Serum and plasma from patients with COVID-19 increased surface expression of cell adhesion molecules. Furthermore, levels of soluble ICAM-1 and E-selectin were elevated in patient serum and tracked with disease severity. The presence of circulating antiphospholipid antibodies was a strong marker of the ability of COVID-19 serum to activate endothelium. Depletion of total IgG from antiphospholipid antibody-positive serum markedly restrained upregulation of cell adhesion molecules. Conversely, supplementation of control serum with patient IgG was sufficient to trigger endothelial activation.Conclusion These data are the first to suggest that some patients with COVID-19 have potentially diverse antibodies that drive endotheliopathy, adding important context regarding thrombo-inflammatory effects of autoantibodies in severe COVID-19. | ||
| 700 | 1 | |a Zuo, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Navaz, Sherwin |e verfasserin |4 aut | |
| 700 | 1 | |a Harbaugh, Alyssa |e verfasserin |4 aut | |
| 700 | 1 | |a Hoy, Claire K. |e verfasserin |4 aut | |
| 700 | 1 | |a Gandhi, Alex A. |e verfasserin |4 aut | |
| 700 | 1 | |a Sule, Gautam |e verfasserin |4 aut | |
| 700 | 1 | |a Yalavarthi, Srilakshmi |e verfasserin |4 aut | |
| 700 | 1 | |a Gockman, Kelsey |e verfasserin |4 aut | |
| 700 | 1 | |a Madison, Jacqueline A. |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jintao |e verfasserin |4 aut | |
| 700 | 1 | |a Zuo, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Maile, Michael D. |e verfasserin |4 aut | |
| 700 | 1 | |a Knight, Jason S. |e verfasserin |4 aut | |
| 700 | 1 | |a Kanthi, Yogendra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 25. Mai |
| 773 | 1 | 8 | |g year:2022 |g day:25 |g month:05 |
| 856 | 4 | 0 | |u https://doi.org/10.1002/art.42094 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.01.18.21250041 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 25 |c 05 | ||
| 953 | |2 045F |a 570 | ||